#### Edgar Filing: Dicerna Pharmaceuticals Inc - Form 4

Dicerna Pha	rmaceuticals Inc									
Form 4										
February 20	, 2014									
FORM	14 INITED S	TATES SE	CUDITIES		• <b>T</b> T A N	JCE C	COMMISSION		PPROVAL	
	UNITEDS	DIAIES SE	Washington			NGE C	UMIMI55IUN	OMB Number:	3235-0287	
Check th if no lon	ger							Expires:	January 31 2005	
subject to Section 7 Form 4 c	<b>SIAIEM</b> 16.		NGES IN BENEFICIAL OWN SECURITIES				Estimated a burden hou response	average Irs per		
Form 5 obligatio may con <i>See</i> Instr 1(b).	tinue. Section 17(a	) of the Publ		ding Com	pany	Act of	e Act of 1934, 1935 or Section 0	1		
(Print or Type)	Responses)									
1. Name and Address of Reporting Person <u>*</u> Weissman James B			2. Issuer Name <b>and</b> Ticker or Trading Symbol Dicerna Pharmaceuticals Inc				5. Relationship of Reporting Person(s) to Issuer			
			RNA]		ne	(Check all applicable)				
			3. Date of Earliest Transaction (Month/Day/Year)				Director 10% Owner X Officer (give title Other (specify below) below)			
	CEUTICALS, INC STREET, BLDG	., 480	24/2013				/	Business Office	er	
	(Street)		Amendment, D d(Month/Day/Yea	-			6. Individual or Jo Applicable Line) _X_ Form filed by C			
WATERTO	OWN, MA 02472						Form filed by M Person			
(City)	(State) (	Zip)	Table I - Non-	Derivative S	Securi	ties Acq	uired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date 2A. Dee (Month/Day/Year) Execution any (Month/		te, if Transact Code	ion(A) or Dis (Instr. 3, 4	sposed	of (D)	Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
			Code V	<sup>7</sup> Amount	or (D)	Price	(Instr. 3 and 4)			
Common Stock	11/05/2013		М	833	A	\$ 3.42	833	D		
Common Stock	01/27/2014		М	11,283	А	\$ 3.24	12,116	D		
Common Stock	01/29/2014		Р	1,000	А	\$ 15	13,116	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

#### Edgar Filing: Dicerna Pharmaceuticals Inc - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	Derivative Expira		Expiration D	Date Exercisable and xpiration Date Aonth/Day/Year)		7. Title and Amoun Underlying Securit (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amo or Num of Sł	
Employee Stock Option (right to buy)	\$ 3.42	01/27/2014		М		11,216	<u>(1)</u>	09/24/2023	Common Stock	11,2	
Employee Stock Option (right to buy)	\$ 3.42	01/27/2014		М		67	(2)	04/27/2022	Common Stock	6	
Employee Stock Option (right to buy)	\$ 3.42	11/11/2013		М		733	(2)	04/27/2022	Common Stock	73	
Employee Stock Option (right to buy)	\$ 3.42	11/11/2013		М		100	(3)	04/27/2022	Common Stock	10	
Employee Stock Option (right to buy)	\$ 3.42	09/24/2013		A	60,000		(3)	09/24/2023	Common Stock	60,0	
Employee Stock Option (right to buy)	\$ 3.42	09/24/2013		A	90,000		<u>(1)</u>	09/24/2023	Common Stock	90,0	

### **Reporting Owners**

Reporting Owner Name / Address	Relationships					
<b>F F</b>	Director	10% Owner	Officer	Other		
Weissman James B C/O DICERNA PHARMACEUTICALS, INC. 480 ARSENAL STREET, BLDG 1, SUITE 120 WATERTOWN, MA 02472			Chief Business Officer			

## Signatures

/ s John Green

\*\*Signature of Reporting Person 02/17/2014

### **Explanation of Responses:**

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

Date

- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Vests 1/48 monthly on last day of each month with a vesting start date of 7/30/2013.
- Vests 25% after the first year anniversary of the vesting start date of 01/01/2012 and the remaining 75% vests at 1/36 per month (2)thereafter.
- (3) The vesting of this option is subject to achievement of pre-established performance goals.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.